The engineered organ has implications for everything from rapid production of immune therapies to new frontiers in cancer or infectious disease research.
blood cancer can result. n the long run, we anticipate that the ability to drive immune reaction ex vivo at controllable rates grants us the ability to reproduce immunological events with tunable parameters for better mechanistic understanding of B cell development and generation of B cell tumors,
the Ingalls Professor of Cancer Genetics at the university School of medicine and a medical oncologist at University Hospitals Case Medical center Seidman Cancer Center. e have developed a drug that acts like a vitamin for tissue stem cells,
Zhang then traveled to UT Southwestern Harold C. Simmons Comprehensive Cancer Center where Willson serves as director.
The third finding came through collaboration between Markowitz and Stanton L. Gerson, MD, director of the Case Comprehensive Cancer Center, UH Seidman Cancer Center,
Finally, the promise of tissue growth could increase survival rates for patients with liver cancer;
the Cancer Prevention & Research Institute of Texas; Inje University; and the Korean National Research Foundation.
Markowitz and Willson, former director of the Case Comprehensive Cancer Center and now director of the Simmons Cancer Center at UT Southwestern, initiated the project to study the potential of inhibiting 15-PGDH as a tissue
#Tumour in a petri dish a way to a personalized cancer treatment Cancer is still one of those diagnoses that make people weak in their knees
That is why innovative cancer treatments are always in the spotlight of attention and that is why scientists have been puzzling how to treat cancer for a long time.
They understand that not every case is the same, individuals need individual treatment. And now scientists from the University of Wisconsin-Madison completed highly successful,
said that this research is one of the first steps of mimicking the body of the cancer patient in a dish.
which involves co-culturing multiple myeloma tumour cells with their surrounding cells that do not have cancer, all from the same patient, in a micro scale petri dish.
Then scientists treated this cancer in a dish with common drug called bortezomib, which is used often to treat myeloma,
so in is a universally fatal cancer. It is treatable but incurable. It rises in the blood marrow due to an accumulation of abnormal,
or testing process, may not help to reach the breakthrough in searching for cure for cancer.
Multiple myeloma is most likely to remain a universally fatal cancer until some major scientific discoveries are made.
However, it can save many multiple myeloma cancer patients the psychological stress of having to try multiple drugs until they find the most effective one.
Cancer is still able to interact with its surroundings as well as treatment, but outside of the body.
Scientists are already thinking how to expand this assay to test responsiveness to different drugs of other cancers as well.
This may not be a tool to cure cancer, but it will surely help cancer patients to receive personalized treatments.
It will reduce stress they get through usual trial and error method and will make treatment that a little bit less tormenting.
neurosurgeons walk a tightrope as they try to take out as much of the cancer as possible
and are not cancer. A summary of the research appears June 17 in Science Translational Medicine. s a neurosurgeon,
the cancer could come back; too much, and the patient can be disabled permanently, says Alfredo Quinones-Hinojosa, M d.,a professor of neurosurgery,
thought OCT might provide a solution to the problem of separating brain cancers from other tissue during surgery.
Kut first built on the idea that cancers tend to be relatively dense, which affects how they scatter
Once they had found the characteristic OCT ignatureof brain cancer, the team devised a computer algorithm to process OCT data and,
nearly instantaneously, generate a color-coded map with cancer in red and healthy tissue in green. e envision that the OCT would be aimed at the area being operated on,
and the surgeon could look at a screen to get a continuously updated picture of where the cancer is
The system can potentially be adapted to detect cancers in other parts of the body, Kut says.
#New tool on horizon for surgeons treating cancer patients Surgeons could know while their patients are still on the operating table
rapidity and specificity of our method, there is great potential for our technology to assist surgeons in the detection of cancer from tissue biopsy samples,
#Cancer Blocked by Halving Levels of Protein Thought To Be ntouchablein a surprising finding, a team of UC San francisco and Stanford university scientists has discovered that a protein thought to be crucial for the body to develop
who holds the Helen Diller Family Chair in Basic Cancer Research, and Maria Barna, Phd, assistant professor of developmental biology and genetics at Stanford, co-senior authors of the new study. he dogma in every textbook was that
said Ruggero, a member of the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC). During translation, strands of MESSENGER RNA (mrna) carry protein-making instructions from genes to ribosomes, the cellular machines in which proteins are made.
In lab-dish experiments, mutations in certain genes known as oncogenes, such as Ras and Myc, reliably ransformnormal mouse cells into cancer-like cells the cells overproliferate,
when they set the stage for the development of cancer. These results were consistent with those seen in eif4e-deficient mice carrying Ras mutations
. effector is developing new treatments for patients with cancer and other serious diseases, in part by characterizing drug action and identifying targets related to the cell translational mechanisms.
It is a very versatile platform to treat melanoma, other kinds of cancers and other diseases.
which will eventually lead to innovative drug therapies for cancer and other diseases i
#Access to electricity and artificial light shortened time of our sleep Science knows that nowadays people tend to sleep less than they used to before modern times.
said Professor Shankar Balasubramanian of the Department of chemistry and the Cancer Research UK Cambridge Institute, who led the research. t had been thought this modification was solely a short-lived intermediate,
The research was supported by Cancer Research UK, the Wellcome Trust and the Biotechnology and Biological sciences Research Council UK e
#New approach holds promise for earlier, easier detection of colorectal cancer Caltech chemists develop a technique that could one day lead to early detection of tumors Chemists at Caltech
have developed a new sensitive technique capable of detecting colorectal cancer in tissue samples a method that could one day be used in clinical settings for the early diagnosis of colorectal cancer.
Colorectal cancer is the third most prevalent cancer worldwide and is estimated to cause about 700,000 deaths every year.
but that has also recently been identified as an early indicator of cancer, especially the development of tumors,
and that, in turn, can lead to cancer. Building on previous work in Barton group, Furst and Barton devised an electrochemical platform to measure the activity of DNMT1 in crude tissue samples those that contain all of the material from a tissue
and the presence of cancer the correlation was with activity. he assay provides a reliable and sensitive measure of hypermethylation,
so this technique could provide a useful route to early detection of cancer when hypermethylation is involved.
portable tests that could be used in the home to catch colorectal cancer in its earliest, most treatable stages.
#Risk of bowel cancer reduced by taking aspirin for Lynch syndrome patients An international study led by The University of Melbourne has confirmed that long-term regular taking of aspirin
or ibuprofen reduces the risk of bowel cancer by more than half for people with the genetic mutation causing Lynch syndrome.
These people have a much higher rate of bowel cancer than the general population and about half would develop the disease without regular screening.
In a paper published in the Journal of the National Cancer Institute University of Melbourne researchers and international collaborators, led by Dr Driss Ait Ouakrim
and Dr Aung Ko Win from the School of Population and Global Health confirmed that those with Lynch syndrome who took aspirin regularly were less likely to develop bowel cancer than Lynch syndrome patients who did not take aspirin.
another nonsteroidal anti-inflammatory drug, were about 60%less likely to develop bowel cancer compared with those who did not take ibuprofen.
if and how lifestyle factors and medications can modify their risk of bowel cancer, Dr Win said. ur data is the first to confirm the finding of a previous international randomised clinical trial that found a protective effect of aspirin on bowel cancer for these high-risk people.
Also, we were able to show the similar protective effect of ibuprofen such as Nurofen on bowel cancer for people with Lynch syndrome,
Dr Win said
#Breakthrough in graphene production could trigger revolution in artificial skin development A pioneering new technique to produce high-quality,
for example, are often overactive in cancer; gene editing could silence these genes to stop a cancer.
Clinicians worry that transplanting stem cells to heal diabetes or Parkinson disease raises the risk of endless cell divisions and cancer.
Removing genes that promote cell division could forestall that danger. Long before those uses reach the clinic,
A team of researchers from the Spanish National Cancer Research Centre (CNIO) have discovered now that telomeres
I believe that crowd-sourced computing will enable more important scientific advances in cancer treatment and clean energy, for example in the future,
Heart disease is the No. 1 cause of death in the United states, killing 40 percent more people than all types of cancer combined.
But while there are routine screens for many types of cancer, there isn a universally adopted test used to check for heart attack risk in people who are not exhibiting symptoms associated with heart disease.
#Tumor-suppressing gene lends insight to cancer treatment Cell duplication and growth is essential to sustaining life,
and can lead to cancer development. The study, published in Nature Communications, could influence how future cancer patients are treated based on their genetic makeup. umors without PTEN are more sensitive to chemotherapies that work by targeting DNA replication,
while normal cells or cancers with active PTEN resist these treatments, said Dr. Wen H. Shen, the study lead investigator and an assistant professor of cell biology in radiation oncology at Weill Cornell. ased on our research,
knowing PTEN status is critical for guiding treatment choices. n the late 1990s, scientists discovered the PTEN gene,
and if loss of PTEN could impact this central process of genome transmission to allow development and progression of cancer.
and Edward Meyer Cancer Center at Weill Cornell. s the DNA double helix unwinds and separates, forming A y-shaped open structure,
Cancer can result when the stress signals accumulate or when cells with unreplicated DNA rush into cell division prematurely to produce an abnormal number of chromosomes in a cell, a condition called aneuploidy.
PTEN function is absent in a wide variety of cancers for example, 70 percent of prostate cancers have PTEN mutation or deletion.
Because of this, researchers are testing PTEN to see if it a marker of aggressive cancer
and for personalized cancer treatment. atients whose cancers have lost PTEN or harbor mutations in the gene are known to have poorer outcomes than patients with active PTEN,
Shen said. ur expectation is that a PTEN blood test in the near future will help clinicians decide on the right therapies for each cancer patient,
and in particular, to benefit this subgroup of cancer patients carrying PTEN mutations. ource: Cornell Universit u
#HIV vaccine: Pushing the Envelope A new study led by scientists at Harvard Medical school and Beth Israel Deaconess Medical center demonstrates that a heterologous prime-boost HIV-1 vaccine regimen protected 50 percent of vaccinated nonhuman primates against challenges with the simian immunodeficiency virus (SIV),
To develop their system the researchers used the information of almost 40,000 breast cancer patients from The netherlands Cancer Registry (NKR, Nederlandse Kankerregistratie), a unique database in which all information about the occurrence,
survival and deaths of all instances of cancer in The netherlands have been registered since 1989. Follow-upwith this system
#Graphene-Based Biosensor Could Detect Cancer within Minutes One of the main reasons why treating most cancers is such a difficult task is our inability to detect its presence before it becomes widespread.
The new, graphene-based immunosensor could soon lead to a quantum leap in cancer diagnosis. Image credit:
researchers at Trinity college Dublin are currently developing a highly-efficient biosensor that could pick up even the slightest presence of cancer within the body in mere minutes.
it took graphene to also make it sensitive to cancer. e showed experimentally that simply the addition of graphene led to a clear increase in the sensor signal, aid Dr. Georg Duesberg,
since it can be adapted to almost any type of disease markers. ven though the SPR sensor is not the only method scientists are currently developing for cancer screening,
thus providing earlier diagnosis and prognosis of conditions such as cancer, said Dr. Andreas Holzinger, another researcher involved in the study.
It a discovery that could unlock secrets into how cancer operates a disease that two in five Canadians will develop in their lifetime. cientists knew that severely injured DNA was taken to specialized ospitalsin the cell to be repaired,
it has irregular cell instructions a scenario that could cause cancer. his process allows cells to survive an injury,
and roads while conducting a study to see what role they might play in causing cancer. e expect that this may allow us to identify targets for a new class of anticancer drugs.?
inflammation and cancer, is reported on today in the research journal Nature Methods. The examination of epigenomes requires mapping DNA interactions with a certain protein in the entire genome.
the team plans to use this technology to study other epigenomic changes involved in inflammation and cancer in the near future.
The innovative approach may lead to more effective therapies with fewer side effects, particularly for diseases such as cancer, heart disease and neurodegenerative disorders.
and cancer as well as to use this structure to screen for drug compounds that are designed to treat these diseases with far fewer side effects,
and when they become dysfunctional it can lead to devastating diseases such as cancer, said Wei Liu,
and make important progress in the fight against cancer and other incurable human diseases. a
Now, researchers at MIT Koch Institute for Integrative Cancer Research and Massachusetts General Hospital (MGH) have created a polymer gel that overcomes this safety concern
Because these immune-system cells play important roles in a wide range of diseases, from diabetes to AIDS to cancer, the achievement provides a versatile new tool for research on T cell function,
a protein that has attracted intense interest in the burgeoning field of cancer immunotherapy, as scientists have shown that using drugs to block PD-1 coaxes T cells to attack tumors.
#Scientists decipher the molecular basis of an as yet incurable leukemia in children Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children.
which has shown already efficiency in other type of cancers. Source: MP s
#Paralyzed men move legs with new noninvasive spinal cord stimulation Five men with complete motor paralysis were able to voluntarily generate step-like movements thanks to a new strategy that non-invasively delivers electrical
giving the option of more personalised diagnosis and treatment to cancer patients.""It's not ready for prime time yet,
#Lab on chip device to shed light on how cancer spreads 19 may 2015these rare circulating tumour cells (CTCS) can be found at low levels in a cancer patient bloodstream
the spread of cancer from one part of the body to another. The new device-which is described in a Nature Methods paper is expected to enable researchers to capture clusters of these cells
melanoma or prostate cancer successfully captured CTC clusters in from 30 to 40 percent of samples from each group.
an observation that could have important implications with the increased attention to immune-system-based cancer therapies. e are only at the beginning of our quest to understand the role and biology of CTC clusters,
About $70 million will go to the National Cancer Institute, a subsection of the NIH, so it can increase its efforts to identify genetic mutations that contribute to a person's cancer risk.
The FDA, for its part, will receive $10 million to improve its databases, as well as the technologies used to analyze DNA.
#HPV Vaccine Is Effective Against Multiple Cancer-Causing Strains The human papillomavirus vaccine, Cervarix, not only has the potential to prevent cervical cancer,
it is also effective against other common cancer-causing stains, according to a recent study. Researchers found that Cervavix was effective aside from just the two HPV types, 16 and 18,
but was effective against other common cancer-causing human papillomaviruses, aside from just the two HPV types, 16 and 18,
including up to 100 percent of those with the immediate precursor grade to cancer. The women were followed for up to four years post-vaccination.
The study is the final report from the Papilloma Trial Against Cancer in Young Adults (PATRICIA), a multinational clinical trial encompassing 14 countries in Europe, the Asia-Pacific region
and the United states. While the trial did not investigate the vaccine's efficacy in males, sexually transmitted HPV causes anogenital and head and neck cancers in both males and females.
and neck cancers now number around 8, 400 in the United states, annually.""The more adolescents are vaccinated,
"Cervical cancer is the fourth most common cancer among women. In the United states, about 12,000 new cases,
and 4, 000 deaths occur annually, according to the SEER database of the National Cancer Institute.
#After Celgene Deal, Juno Revs Armored CAR For Ovarian Cancer Trial Juno Therapeutics has built remarkable momentumncluding last week much-dissected $1 billion deal with Celgenepon
engineered to become better cancer killers, and reinserted into the patient. CAR stands for chimeric antigen receptor,
an upcoming Phase 1 trial will treat patients with relapsed ovarian cancer, one of many solid-tissue tumors that are expected to be a much higher hurdle for the field of cell-based immunotherapy.
Though T cells still have much left to prove in blood-borne cancers, which are relatively rare,
scientists want to use the technology to target a cancer like ovarian, which will kill an estimated 14,000 women in the U s. this year. he big question is, an you cross over to solid tumors?'
'says Renier Brentjens, the director of cellular therapeutics at Memorial Sloan Kettering Cancer Center in New york and a Juno scientific founder.
or September he will begin treating ovarian cancer patients with armored CAR-T cells, engineered to send out a chemical signal that recruits the patientsnon-engineered T cells to come join the attack. ee going full force forward,
Just as it did with some of the blood-cancer programs now under Juno roof, Sloan Kettering will run the trial.
T cell therapies have treated relatively rare blood-borne cancers. If that the extent of the treatment reach,
which account for about 90 percent of all cancers. The American Cancer Society estimates that ovarian cancer is the fifth-deadliest in the U s. he animal data have been compelling,
and we want to get this into patients, says Harr. The Sloan Kettering trial won be the first test of engineered T cells in solid tumors.
a cancer that develops from immature nerve cells. In the case of Brentjens cells, the protein that signals to other T cells to help with the attack, could be the difference.
Researchers at the University of California, Los angeles published work late last year that showed why certain patients responded well to a different kind of cancer immunotherapyn antibody called pembrolizumab (Keytruda.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011